Soluble factors secreted by differentiating embryonic stem cells stimulate exogenous cell proliferation and migration by Alyssa V Ngangan et al.
Ngangan et al. Stem Cell Research & Therapy 2014, 5:26
http://stemcellres.com/content/5/1/26RESEARCH Open AccessSoluble factors secreted by differentiating
embryonic stem cells stimulate exogenous cell
proliferation and migration
Alyssa V Ngangan1, James C Waring1, Marissa T Cooke1, Christian J Mandrycky1 and Todd C McDevitt1,2*Abstract
Introduction: Stem cells are being investigated as catalysts of tissue regeneration to either directly replace or
promote cellularity lost as a result of traumatic injury or degenerative disease. In many reports, despite low
numbers of stably integrated cells, the transient presence of cells delivered or recruited to sites of tissue
remodeling globally benefits functional recovery. Such findings have motivated the need to determine how
paracrine factors secreted from transplanted cells may be capable of positively impacting endogenous repair
processes and somatic cell responses.
Methods: Embryonic stem cells were differentiated as embryoid bodies (EBs) in vitro and media conditioned by EBs
were collected at different intervals of time. Gene and protein expression analysis of several different growth factors
secreted by EBs were examined by polymerase chain reaction and enzyme-linked immunosorbent assay analysis,
respectively, as a function of time. The proliferation and migration of fibroblasts and endothelial cells treated with
EB conditioned media was examined compared with unconditioned and growth media controls.
Results: The expression of several growth factors, including bone morphogenic protein-4, insulin-like growth factors
and vascular endothelial growth factor-A, increased during the course of embryonic stem cell (ESC) differentiation
as EBs. Conditioned media collected from EBs at different stages of differentiation stimulated proliferation and
migration of both fibroblasts and endothelial cells, based on 5-bromo-2′-deoxyuridine incorporation and transwell
assays, respectively.
Conclusions: Overall, these results demonstrate that differentiating ESCs express increasing amounts of various
growth factors over time that altogether are capable of stimulating mitogenic and motogenic activity of exogenous
cell populations.Introduction
Tissue damage in adult mammalian species typically
results in the formation of scar tissue that prohibits the
recovery of normal tissue function. Cellular infiltration,
matrix deposition, angiogenesis, and remodeling events
that transpire following tissue injury are stimulated to pre-
vent further damage and preserve tissue function; how-
ever, such endogenous processes are typically insufficient
to fully promote functional regeneration in adult mam-
mals. Efforts to augment this process via transplantation* Correspondence: todd.mcdevitt@bme.gatech.edu
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reproduction in any medium, provided the orof various cell populations with the ability to integrate and
restore function to damaged tissues have been attempted
in a number of different mammalian tissues [1-3], yet the
percentage of cells that successfully engraft and persist
within host tissues is typically quite low (<1%) [4-6].
However, despite the transient presence of exogenously
delivered cells, persistent macroscopic functional effects
and benefits have been commonly observed in a variety
of different tissues.
In the absence of tissue integration, the beneficial
impact of transplanted cell populations within regions
of tissue damage is most probably due to the local
secretion of paracrine factors produced by the exogen-
ously delivered cells. Several studies have investigated
the influence of paracrine factors secreted by cells ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Ngangan et al. Stem Cell Research & Therapy 2014, 5:26 Page 2 of 12
http://stemcellres.com/content/5/1/26interest in preserving tissue integrity and function by
attenuation of apoptosis and adverse remodeling [7-10].
Additionally, transplantation of exogenous stem cells and
their differentiated progeny capable of secreting a potent
combination of soluble factors can augment chemotaxis of
host cells, including endothelial cells (ECs) and fibroblasts
that are known to participate in tissue remodeling pro-
cesses [11-14]. Further characterization of the soluble
milieu produced by several exogenous cell types imple-
mented in cell transplantation therapies has identified
the presence of distinct secreted growth factors and
chemokines known to be involved in wound healing, in-
cluding vascular endothelial growth factor-A (VEGF-A),
transforming growth factor beta, and fibroblast growth
factor-2 (FGF-2) [15-17]. Like other stem and progeni-
tor cells, pluripotent embryonic stem cells (ESCs) and
ESC-derived cells secrete paracrine factors capable of
attenuating tissue injury in a variety of settings [18-20].
Therefore, having established a paracrine mode of action
for stem cells, including ESCs, there is increasing interest
in the specific composition of the extracellular stem cell
environment, specifically the secretome and glycome, in
efforts to understand the mechanism(s) of action whereby
stem cells impart therapeutic benefits [14,21-24]. Interest-
ingly, mammalian embryos are inherently capable of en-
dogenous functional tissue restoration and scarless wound
healing, phenomena not commonly observed in most adult
species, indicating that unique factors present in the em-
bryonic environment may promote these distinctive pro-
cesses [25-27]. In vitro differentiation of ESCs through the
formation of multicellular aggregates, referred to as embry-
oid bodies (EBs), mimics aspects of embryogenesis, includ-
ing behaviors such as the proliferation, differentiation and
morphogenesis of pluripotent cells [28-30]. Thus, as ESCs
differentiate within EBs to primitive cell phenotypes, the
accompanying profile of molecules secreted by the cells
might also be expected to reflect the dynamic morphogenic
nature of the native embryonic environment [31].
The objective of this study was thus to determine the
relative abundance of specific soluble factors secreted by
ESCs as a function of differentiation and to examine the
effects of these ESC-derived factors on exogenous cell
types typically involved in wound repair and tissue re-
modeling, specifically fibroblast and ECs. As ESCs dif-
ferentiated within EBs, the amounts of several secreted
growth factors known to stimulate mitogenic and moto-
genic activity of somatic cells were quantified. In addition,
the effects of EB-secreted factors on fibroblast and EC
proliferation and migration were assayed. Overall, charac-
terizing the identity and relative potency of growth factors
secreted by differentiating ESCs on exogenous cell types
may provide new insights into molecular mechanisms
of how differentiated derivatives of pluripotent cells can
positively impact tissue repair for acute injuries andchronic diseases and can lead to the development of a
novel class of regenerative molecular therapies.
Materials and methods
Mouse embryonic stem cell culture
D3 murine ESCs were cultured on 0.1% gelatin-coated
plates in complete medium consisting of Dulbecco’s modi-
fied Eagle’s medium (Mediatech, Manassas, VA, USA) sup-
plemented with 15% fetal bovine serum (Hyclone, Logan,
UT, USA), 2 mML-glutamine (Mediatech), 1× non-essential
amino acids (Mediatech), 100 U/ml penicillin (Mediatech),
100 mg/ml streptomycin (Mediatech), 0.25 mg/ml ampho-
tericin (Mediatech), 0.1 mM β-mercaptoethanol (MP
Biomedicals, LLC, Cleveland, OH, USA), and 103 U/ml
leukemia inhibitory factor (ESGRO; Millipore, Billerica,
MA, USA). Cells were incubated in a humidified environ-
ment at 37°C in 5% carbon dioxide and passaged with 0.05%
trypsin–ethylenediamine tetraacetic acid (Mediatech) at ap-
proximately 70% confluence. To initiate ESC differenti-
ation, EBs were formed from a single-cell suspension of
4 × 106 cells in 10 ml differentiation medium (complete
medium without leukemia inhibitory factor) by spontan-
eous aggregation on a rotary orbital shaker. EBs were cul-
tured in 100 mm Petri dishes on a rotary orbital shaker
(Lab-Line Lab Rotator; Barnstead, Dubuque, IA, USA)
held constant at 40 ± 2 rpm [32,33]. Rotary shakers were
calibrated daily to ensure constant speed throughout the
course of EB culture, and the medium was completely ex-
changed every 2 days after collecting EBs via gravity-
induced sedimentation in 15 ml conical tubes.
Collection of embryoid body conditioned medium
EBs differentiated for 4, 7, or 10 days were collected
(as described above), rinsed three times with phosphate-
buffered saline (PBS, pH 7.4), and cultured for an additional
2 days with a modified serum-free differentiation
medium – hereafter referred to as unconditioned medium
(uCM) – consisting of phenol red-free, low-glucose (2.8 mM)
Dulbecco’s modified Eagle’s medium (Invitrogen, Life
Technologies, Grand Island, NY, USA), supplemented
with 2 mML-glutamine, 1× non-essential amino acids, 100
U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml
amphotericin, and 1 mg/ml bovine serum albumin (Fraction
V; MP Biomedicals). After 48 hours of conditioning, EBs
were collected by gravity-induced sedimentation and the EB
conditioned medium (CM) (~10 ml) was transferred to
a fresh conical tube. The EB-CM was centrifuged for
5 minutes at 10,000 rpm at 4°C to remove cellular debris
and the supernatant fraction was transferred to a fresh 15 ml
conical tube and stored at −20°C prior to further analysis.
Embryoid body count
At each EB-CM collection time point, EBs were washed
twice with PBS and resuspended in 2 ml PBS. A 200 μl
Table 1 Primer nucleotide sequences
Primer Nucleotide sequence (5′ to 3′)
Gapdh Forward GCC TTC CGT GTT CCT ACC
Reverse GCC TGC TTC ACC ACC TTC
Oct-4 Forward CCG TGT GAG GTG GAG TCT GGA G
Reverse GCG ATG TGA GTG ATC TGC TGT AGG
Afp Forward CAC ACC CGC TTC CCT CAT CC
Reverse TTC TTC TCC GTC ACG CAC TGG
Bmp-4 Forward CTG GCC CGG AAG CTA GGT GAG TT
Reverse GAG GGC CAG AGA CTG GAT CGC
Fgf-2 Forward AGC GAC CCA CAC GTC AAA CTA C
Reverse CAG CCG TCC ATC TTC CTT CAT A
Igf-1 Forward TCC GCC AGG TTG CCT CTA G
Reverse GGA AGC AGG TGG ATG GTC AG
Igf-2 Forward TCA AAG AGT TCA GAG AGG
Reverse CAA CCA TCA GTG AAT CAA A
Pdgfb Forward ATC GCC GAG TGC AAG ACG CG
Reverse AAG CAC CAT TGG CCG TCC GA
Vegfa Forward TGC ACC CAC GAC AGA AGG
Reverse GCA CAC AGG ACG GCT TGA
Forward and reverse primer nucleotide sequences for the polymerase chain
reaction amplification of glyceraldehyde-3-phosphate dehydrogenase (Gapdh),
Octamer-4 (Oct-4), α-fetoprotein (Afp), bone morphogenetic protein-4 (Bmp-4),
fibroblast growth factor-2 (Fgf-2), insulin-like growth factor-1 and factor-2
(Igf-1, Igf-2), platelet-derived growth factor-B chain (Pdgf-b), and vascular
endothelial growth factor-A (Vegfa). All reverse transcriptase-polymerase chain
reactions performed with an annealing temperature of 58°C.
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order to reduce the density of EBs for visual counting in
a 24-well plate. The final diluted volume of EBs (1 ml)
was added at 200 μl per well, and the number of EBs per
well (five wells) was counted. The number of diluted EBs
was counted at 4× magnification using a Nikon TS100
microscope (Nikon, Inc., Melville, NY, USA) and the
total number of EBs per plate was calculated based on
the respective dilution factor used.
RNA extraction and quantitative reverse
transcriptase-polymerase chain reaction
RNA was extracted from undifferentiated ESCs (day 0)
and from serum-free EBs on days 6, 9, and 12 of rotary
culture utilizing the RNeasy Mini Kit (Qiagen, Valencia,
CA, USA) and was analyzed on a NanoDrop spectropho-
tometer (NanoDrop, Wilmington, DE, USA) for concen-
tration and purity from 260 nm and 280 nm absorbance
readings. Complementary DNA was reverse transcribed
using 1 μg total RNA in conjunction with the iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) on the
iCycler Thermal Cycler (Bio-Rad). Quantitative reverse
transcriptase-polymerase chain reaction was performed
using SYBR Green with the MyIQ cycler (Bio-Rad). Pri-
mer sets were designed using Beacon Designer software
(Premier Biosoft, Palo Alto, CA, USA) for pluripotency
markers (Octamer-4, Oct-4) and differentiation markers
(α-fetoprotein, Afp) as well as for the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Add-
itionally, growth factor primer sets were also designed, in-
cluding bone morphogenetic protein-4 (Bmp-4), fibroblast
growth factor-2 (Fgf-2), insulin-like growth factor-1 and
factor-2 (Igf-1, Igf-2), platelet-derived growth factor-B chain
(Pdgfb), and vascular endothelial growth factor-A (Vegfa).
Each primer pair was independently validated with appro-
priate positive cell controls. Relative levels of gene expres-
sion were calculated compared with undifferentiated ESC
samples and were normalized to Gapdh using the ΔΔCt
method [34]. All primer sequences used are presented in
Table 1.
Embryoid body conditioned medium protein
quantification
The total protein content of EB-CM was analyzed using a
bicinchoninic acid assay kit (Thermo Scientific, Pittsburgh,
PA, USA). According to the manufacturer’s protocol, a
25 μl sample was incubated with 200 μl bicinchoninic acid
solution for 30 minutes. Absorbance readings were taken
at 562 nm using a Molecular Devices SpectraMax M2e mi-
croplate reader and SoftMax Pro v5 microplate data acqui-
sition software (Molecular Devices, Sunnyvale, CA, USA).
The absorbance readings of the EB-CM samples were
compared against a standard curve (0 to 2,000 μg/ml) gen-
erated using bovine serum albumin in order to calculateabsolute protein concentrations. To determine the amount
of protein secreted by the EBs during conditioning, the
protein content of uCM was subtracted from all of the
EB-CM samples.
Enzyme-linked immunosorbent assay kits were used to
quantify the amount of proteins of interest contained
within the EB-CM, specifically BMP-4, IGF-2 and VEGF-A
(DuoSet; R&D Systems, Minneapolis, MN, USA). Briefly,
capture antibody was adsorbed onto a MaxiSorp™ Immuno
96-well plate (Nunc, Thermo Scientific), followed by a
blocking step, incubation with 100 μl sample, and bind-
ing of analyte to a biotinylated detection antibody. The
concentrations of capture and detection antibodies used
were dictated by the DuoSet protocol for each protein:
2 μg/ml and 1 μg/ml for BMP-4, 4 μg/ml and 200 ng/ml
for IGF-2, and 400 ng/ml and 100 ng/ml for VEGF-A.
uCM was used as the diluent for the standard curve
samples. The amount of analyte was assessed using the
colorimetric reaction of peroxidase and tetramethylben-
zidine at an absorbance reading of 450 nm. The absorb-
ance values for each EB-CM sample were compared
with the standard curve to establish the protein analyte
content, which was normalized to the EB number and
reported as picograms of protein per 1,000 EBs.
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NIH/3T3 fibroblasts were cultured on tissue culture
dishes in 3T3 growth medium containing Dulbecco’s
modified Eagle’s medium supplemented with 10% bovine
growth serum, 4 mML-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and 0.25 μg/ml amphotericin.
Human umbilical vein endothelial cells (HUVECs) were
cultured on gelatin-coated tissue culture dishes in EC
growth medium, consisting of MCDB131 basal medium
supplemented with 5% fetal bovine serum, 100 μg/ml
streptomycin, 0.25 μg/ml amphotericin, 2 mML-glutamine,
1 mg/ml hydrocortisone (Sigma, St. Louis, MO, USA),
2 ng/ml FGF-2 (PeproTech, Princeton, NJ, USA), 10 ng/ml
epidermal growth factor (Gibco, Life Technologies),
2 ng/ml IGF-1 (Gibco), 1 ng/ml VEGF-A (Sigma), and
50 mg/ml ascorbic acid (Sigma).
For proliferation studies, NIH/3T3 fibroblasts and
HUVECs were cultured to approximately 50% confluence
in two-chamber glass slides (BD Bioscience, San Jose,
CA, USA), at which point growth media were removed
and the cells were rinsed three times in PBS. Cells were
then starved overnight in low-serum media, followed by
an 18-hour pulse with 10 μM 5-bromo-2′-deoxyuridine
(BrdU) in EB-CM from different time points as well as
control media. After the 18-hour pulse, cells were
rinsed with PBS and fixed in 70% ethanol with 2.3 M
HCl for 10 minutes at room temperature, rinsed in PBS
three times, and incubated with mouse anti-BrdU primary
antibody (Molecular Probes, Life Technologies) for
1 hour at room temperature. Following primary anti-
body incubation, the cells were incubated with donkey
anti-mouse secondary antibody conjugated to Alexa-
Fluor®488 (Invitrogen) for 2 hours at room temperature,
counterstained with 10 μg/ml Hoechst 33258 (Sigma), and
then coverslipped using GelMount (Electron Microscopy
Sciences, Hatfield, PA, USA).
Stained slides were imaged using a Nikon 80i upright
microscope with a SPOTFlex digital camera and SPOT
Advanced Software (Nikon) using both the fluorescein
isothiocyanate (FITC) and 4′,6-diamidino-2-phenylindole
(DAPI) channels. Nuclei counts were performed on 4′,6-
diamidino-2-phenylindole and fluorescein isothiocyanate
filtered images to calculate the percentage of BrdU-
positive nuclei (fluorescein isothiocyanate) per field
(six fields per chamber) using the Count Nuclei mod-
ule within the MetaMorph software package (Molecu-
lar Devices).
Transwell migration assays
For migration studies, NIH/3T3 fibroblasts and HUVECs
were each grown to ~80% confluence, inactivated with
10 μg/ml mitomycin-C in serum-free media (2 hours at
37°C in 5% carbon dioxide) and cultured overnight in their
respective growth media. Immediately prior to theinitiation of transwell migration studies, cells were also
fluorescently labeled in serum-free media with 1 μM
CellTracker® Green (Molecular Probes) for 20 minutes
at 37°C, followed by a 30-minute incubation in growth
media.
HTS Fluroblok transwell culture inserts (24-well, 8 mm
pore size; Falcon, BD Biosciences) were prepared with a
300 μl single-cell suspension (7.5 × 104 3T3 cells or 1 × 105
HUVECs) in growth media (loaded in the top chamber).
The bottom of the transwell chamber was filled with
800 μl EB-CM sample or control media; cells’ respective
growth media were used as positive controls, while
uCM served as a negative control. Transwell culture
plates were incubated for 24 hours at 37°C and 5% hu-
midity, and fluorescent microscopy images of the bot-
tom of wells were taken every 6 hours using a Nikon TE
2000 inverted microscope equipped with a SpotFLEX
digital camera and SPOT software (Nikon). The number
of cells that migrated through the porous membrane
were counted for each transwell sample (three fields of
view) using ImageJ (open source program, NIH,
Bethesda, MD, USA) and normalized per square
millimeter.
Statistical analysis
All experimental samples were analyzed with n = 6, with
data presented as mean ± standard error. Statistical sig-
nificance was determined using SYSTAT 12 (SYSTAT
Software, Inc., San Jose, CA, USA) employing an analysis
of variance test with post-hoc Tukey analysis to deter-
mine significance (P < 0.05).
Results
Embryoid body differentiation
Preliminary studies indicated that EBs failed to initially
form well in serum-free media and did not survive for
more than 48 hours after being switched to serum-free
conditions, especially at earlier stages of differentiation
(that is, days 4 or 7). A protocol for forming and main-
taining EBs in serum-containing media before switching
to serum-free media for conditioning was thus used for
all subsequent studies (Figure 1A). EBs cultured for up
to 48 hours with serum-free medium at different stages
of differentiation were morphologically similar to their
cohorts that remained in serum-containing media for
the same period of time (Figure 1B). As is normally
observed, EBs increased in size during the course of
differentiation (~250 μm diameter at day 6 compared
with ~500 μm at day 12), but there were no observed
differences in the size of EBs cultured in serum-free media
for 2 days compared with EBs in serum-containing media
(Figure 1B). The number of EBs per 100 mm Petri dish
(~5 × 103 EBs) also did not vary significantly over time in
serum-containing or serum-free media, indicating that
Figure 1 Embryoid body differentiation and conditioned media collection. (A) Embryoid bodies (EBs) were cultured on a rotary orbital
shaker at 40 rpm for 4, 7, and 10 days in serum-containing media, at which point the EBs were switched to serum-free media and cultured for an
additional 2 days. After 6, 9, or 12 days of differentiation, EB conditioned media were collected for further analysis. (B) EBs cultured with (top row)
or without (bottom row) serum were similar in size, shape, and morphology at each of the time points examined. Scale bars = 500 μm (panel)
and 100 μm (inset). (C) The number of EBs remained relatively constant per culture (~5 × 103 EBs/plate) independent of the culture media used.
(D, E) Similar EB differentiation in both media conditions was confirmed by polymerase chain reaction analysis, which revealed a significant
decrease in the pluripotent marker Oct-4 by day 12 compared with day 6 and a significant increase in endoderm marker Afp by day 12 compared
with day 6 for EBs cultured under both conditions. Results indicate the mean ± standard error (n = 6). Analysis of variance: *P < 0.05; Student t test:
#t < 0.05. AFP, α-fetoprotein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Oct-4, Octamer-4.
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maintenance of EBs in culture and that similar numbers
of EBs were present during serum-free media condition-
ing (Figure 1C). Most importantly, the expression of
pluripotent markers decreased over the course of differ-
entiation, whereas various markers for differentiated
lineage were increasingly expressed with EB culture
time. For example, Oct-4, a pluripotent transcription
factor, exhibited a similar pattern of decreasing expres-
sion for both EB culture conditions as differentiation
proceeded (Figure 1D). At early time points, days 6 and 9,
Oct-4 gene expression levels were significantly decreased
between serum and serum-free EB cultures (P ≤ 0.027),
but by day 12 Oct-4 gene expression was no longer sig-
nificantly different between these groups although bothwere decreased compared with their respective day 6 EB
cultures (P ≤ 0.025). In addition, expression of differen-
tiated markers such as Afp, a marker of primitive and
definitive endoderm, was increased by day 12 in both
culture conditions compared with day 6 (P ≤ 0.034), yet
between both EB culture conditions the Afp expression at
each time point examined was similar (Figure 1E). Thus,
switching EB cultures to serum-free medium for up to
48 hours did not significantly alter the differentiation of
ESCs based on morphological and phenotypic analysis.
Growth factor gene expression analysis
Overall, gene expression changes for several growth
factors expressed by EBs generally increased as differ-
entiation proceeded, measured by quantitative reverse
Figure 2 Growth factor gene expression by differentiating embryoid bodies. Polymerase chain reaction analysis indicated that the gene
expression of several growth factors increased over time during embryonic stem cell (ESC) differentiation within embryoid bodies (EBs) (A, B, C)
while others decreased relative to ESCs during early differentiation and then increased as differentiation progressed (D, E, F). The relative values
of expression are reported as the relative fold-changes by EBs compared with the starting population of undifferentiated ESCs. Results indicate
the mean ± standard error (n = 6). Analysis of variance: *P < 0.05, #P < 0.001, and †P < 0.05 compared with ESCs. BMP-4, bone morphogenic protein;
FGF-2, fibroblast growth factor-2; IGF, insulin-like growth factor; PDGF-B, platelet-derived growth factor-B; VEGF-A, vascular endothelial growth
factor-A.
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in growth factor gene expression compared with ESCs
were observed for Igf-1 and Igf-2: Igf-1 expression in-
creased ~13-fold and ~29-fold by day 9 (P = 0.009) and
day 12 (P = 6.58 × 10−6) (Figure 2A), and Igf-2 expres-
sion increased ~126-fold by day 12 (P ≤ 7.43 × 10−5)
(Figure 2B). Vegfa gene expression was modest relative
to Igf, yet demonstrated significant increases at day 9
(~5-fold) and day 12 (~5-fold) compared with both
ESCs (P ≤ 6.37 × 10−6) and day 6 EBs (P ≤ 9.19 × 10−6)
(Figure 2C). In some cases, gene expression of several
growth factors was initially reduced during early EB dif-
ferentiation relative to ESCs, but then increased as EB
differentiation progressed. The levels of Bmp-4, Fgf-2
and Pdgfb gene expression were decreased by 3.3-fold,
twofold, and 50-fold, respectively, at day 6 compared
with ESCs (P ≤ 0.015) (Figure 2D,E,F). At day 9, levels of
Bmp-4 and Fgf-2 expression were similar to day 6 levels,
about one-half that of ESCs (P = 4 × 10−3), while Pdgfbexpression was increased compared with day 6 (P ≤ 0.001).
By day 12, all three genes (Bmp-4, Fgf-2, and Pdgfb)
were increased in expression compared with day 6 EBs
(P ≤ 0.001), but were similar to undifferentiated ESC levels.
Despite the specific differences in individual growth fac-
tor gene expression patterns, all of the aforementioned
growth factors generally increased as ESC differenti-
ation transpired.
Protein characterization of embryoid body conditioned
medium
Over the course of EB differentiation, the total amount
of secreted protein content in the conditioned media did
not vary significantly, with results from bicinchoninic acid
analysis measuring consistently within a range of 150 to
225 μg/ml (Figure 3A). Based on SDS-PAGE analysis,
minor differences were apparent in the molecular content
of EB-CM from different stages of differentiation, espe-
cially species between 10 and 20 kDa, corresponding to
Figure 3 Protein secretion by embryoid bodies into conditioned media. (A) Total protein content of the conditioned medium (CM)
collected at each time point examined as determined by bicinchoninic acid did not significantly vary over time. (B) Enzyme-linked immunosorbent
assay results revealed that BMP-4 protein content was similar as embryoid body (EB) differentiation progressed over time. (C, D) Between EB-CMs, IGF-2
protein increased significantly over time in CM at day 12 (CM 12) compared with CM at day 6 (CM 6) and at day 9 (CM 9); VEGF-A increased in CM 12
with significance compared with only CM 6. Results indicate the mean ± standard error (n = 6). Analysis of variance: *P < 0.05 compared with CM 6 and
CM 9, †P < 0.05 compared with CM 6. BMP-4, bone morphogenic protein; IGF, insulin-like growth factor; VEGF-A, vascular endothelial growth factor-A.
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(Additional file 1). Consistent with PCR analysis,
Enzyme-linked immunosorbent assays indicated not-
able changes in the quantities of specific growth factor
proteins in EB-CM that exhibited large fold-changes in
gene expression, namely BMP-4 and IGF-2. VEGF-A
was also examined due to significant gene expression
changes during EB differentiation, as well as its previ-
ous examination in several stem cell conditioned media
studies [15-17]. Generally, the secretion of IGF-2 and
VEGF-A proteins both increased as EB differentiation
progressed, corresponding to similar increases in gene
expression, whereas BMP-4 content in CM did not change
significantly over time (Figure 3B,C,D). Specifically, EBs at
earlier stages of differentiation secreted similar amounts
of IGF-2 in CM at day 6 and at day 9 (CM6, CM 9;
~6 pg/1,000 EBs), but at later stages of differentiation,
day 12 EBs produced more IGF-2 (~24 pg/1,000 EBs)
compared with both earlier time points. VEGF-A secre-
tion by EBs followed a similar trend, as the protein level
was increased in CM at day 12 (CM 12; 2.3 pg/1,000 EBs)
compared with CM 6 (0.1 pg/1,000 EBs; P = 0.029). Thus,
despite the similar amount of total protein secreted by
EBs at different stages of differentiation, specific growth
factors were differentially expressed over time.
Mitogenic activity of embryoid body conditioned medium
Following molecular composition analysis of EB-CM,
somatic cells were treated with EB-CM to assess the mi-
togenicity of EB secreted factors. As expected, fibroblast
growth medium (containing 10% bovine growth serum)
stimulated BrdU incorporation of approximately 90% of
the cells. CM 6 and CM 12 induced significantly more
incorporation of BrdU (~60%) by fibroblasts compared
with uCM (~25%, P ≤ 4.54 × 10−4), while CM 9 stimu-
lated significantly less proliferation (~37% of fibro-
blasts) compared with CM 6 and CM 12 (Figure 4A).The influence of EB-secreted factors on proliferation of
a more tissue-specific cell type (ECs) was additionally
examined. In response to EC growth media, ~55% of
ECs were BrdU-positive, whereas ECs treated with CM
6 and CM 9 resulted in ~30% BrdU-positive cells, simi-
lar to the percentage stimulated by uCM (Figure 4B).
However, CM 12 stimulated significantly more HUVEC
DNA synthesis (~40%) compared with the other EB-
CM samples (P ≤ 0.002) and uCM (P = 1.43 × 10−4). All
together, these results indicate that EB-CM generally
exerted a more potent effect on fibroblast proliferation,
and EB-CM collected from more differentiated EBs en-
hanced the proliferation of ECs.
Motogenic potential of embryoid body conditioned
medium
The chemotactic response of somatic cells to factors se-
creted by differentiating EBs was assessed using a transwell
assay (Figure 5). Quantitative fluorescent spectroscopy
analysis showed that all CM samples stimulated more fi-
broblasts (~27,000 to 30,000 cells) to migrate after 6 and
12 hours of incubation compared with uCM (~16,000
cells, P < 0.05; Figure 5A), but by 24 hours of treatment
only CM 9 stimulated more cells than uCM (~23,000 total
cells, P = 0.008). Further assessment of the images taken at
24 hours illustrated 3T3 arrangement in clusters with
extended processes with EB-CM treatment compared with
single rounded cells sparsely scattered in transwells con-
taining uCM (Figure 5B). The results from the transwell
assay were similar to those obtained from an independent
fibroblast scratch wound assay, where CM 9 stimulated
significant wound closure by 24 hours compared with
uCM (Additional file 2). Overall, the EB-CM increased
fibroblast migration and modulated the morphology of
both individual cells and cell clusters.
To further evaluate the motogenic effects of EB-CM
on other cell types important in tissue remodeling, ECs
Figure 4 Proliferation of exogenous cell types treated with embryoid body conditioned medium. (A) Conditioned medium at day 6 (CM 6)
and at day 12 (CM 12) increased fibroblast proliferation compared with unconditioned medium (uCM). CM at day 9 (CM 9) elicited less mitogenic
response compared with CM 6 and CM 12. (B) Early time points of embryoid body (EB)-CM did not significantly induce endothelial cell proliferation
compared with uCM, whereas CM 12 exhibited significantly greater proliferative response than all other EB-CMs and uCM. Results indicate
the mean ± standard error (n = 6). Top row: phase images, scale bar = 50 μm. Bottom row: fluorescent images, blue = Hoechst stain, green =
5-bromo-2′-deoxyuridine (BrdU)-positive cells, scale bar = 50 μm. Dashed line, % BrdU-positive cells stimulated by the respective cell type’s
growth media. Analysis of variance: *P < 0.05 compared with uCM; #P < 0.05 compared with growth media; †P < 0.05 compared with CM 6
and CM 12; ‡P < 0.05 compared with CM 6 and CM 9. HUVEC, human umbilical vein endothelial cell.
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the migration experiment, each of the EB-CM samples
stimulated more HUVEC migration than uCM (P < 0.05,
Figure 5C). Comparisons between each of the EB-CM
samples at 6-hour and 12-hour time points indicated
similar motogenic induction since the numbers of mi-
grated cells (~4,000 to 4,800 cells) were not significantly
different. However, by 24 hours the number of migrated
cells induced by CM 12 was greater than that by CM 6
and CM 9, due to the decreased migration between 12
and 24 hours in cells exposed to CM from earlier time
points (Figure 5C). Fluorescent images illustrate that
HUVECs in EB-CM were organized as clusters of larger,
more spread cells, compared with the more round and
individually distinct HUVECs in uCM. Additional exam-
ination of EC morphology after 24 hours revealed that
CM 12 treatment yielded cells arranged in large clusters,
while cells in CM 6 and CM 9 grouped in smaller clusters
(Figure 5D).
Despite similar concentrations of total secreted protein
in EB conditioned media collected at all time points of
differentiation, different cell types responded quite dif-
ferently to the ESC secreted factors. The number of 3T3
fibroblasts that migrated was about 10-fold higher than
the number of migrating HUVECs throughout the trans-
well studies despite inoculation with similar numbers of
starting cells (7.5 × 104 3 T3 cells, 1 × 105 HUVECs). Over-
all, the results of the migration assays revealed that EB-CM collected at different stages of EB differentiation con-
tained chemotactic factors capable of stimulating the mi-
gration of different cell types.
Discussion
This study examined several of the growth factors that
were differentially expressed by differentiating ESCs and
the impact of this complex mixture of secreted factors
on different somatic cell types found in most tissues.
ESC transplantation has been widely studied for the re-
population of tissues undergoing remodeling; however,
the number of ESCs that integrate and differentiate
within the host tissue remains quite low [35,36]. Several
studies have examined the potency of ESC-secreted
molecules and their impact on cell and tissue physi-
ology, including inhibition of apoptosis, rescue of con-
genital defects, and cardioprotection following myocardial
infarction [18-20], as well as suppressing seizure activity
[37]. Previous reports of ESC-secreted factors generally
examined paracrine actions of undifferentiated ESCs in
monolayer culture [21,38]. However, upon transplantation
in vivo, the molecular environment within the injured
tissue is more probably prone to induce differentiation
rather than to maintain pluripotency, thus modulating
the paracrine factors released in a manner more analogous
to EB differentiation.
In this study, changes in secreted factor production
coincident with EB differentiation were analyzed for
Figure 5 Migration of exogenous cell types in response to embryoid body conditioned medium. (A) Fibroblast migration was stimulated
by embryoid body (EB) conditioned medium (CM) collected from different days of differentiation compared with unconditioned medium (uCM)
up to 12 hours, but at 24 hours only CM at day 9 (CM 9) induced greater cell migration compared with uCM. (B) After 24 hours, EB-CM promoted
the formation of fibroblast network structures compared with cells treated with uCM, which remained more as single cells. (C) Endothelial cell
migration was stimulated by all of the EB-CM compositions compared with uCM. By 24 hours, CM at day 12 (CM 12) induced significantly more
cells to migrate compared with CM at day 6 (CM 6) and CM 9. (D) After 24 hours, endothelial cells treated with EB-CM prompted cells to cluster
whereas the uCM did not influence the organization of endothelial cells. Results indicate the mean ± standard error (n = 6). Analysis of variance:
*P < 0.05 compared with all EB-CM time points; #P < 0.05 compared with CM 6 and CM 9; †P < 0.05 compared with CM 9. HUVEC, human umbilical
vein endothelial cell.
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and mitogenicity of fibroblasts and ECs. The gene expres-
sion of EBs and protein profiles of EB conditioned media
demonstrated differential representation of several growth
factors as differentiation progressed. Analysis of Bmp-4
gene expression exhibited significant increases over the
time course of differentiation by day 12 EBs, yet the
amount of BMP-4 protein present in CM from each stage
of differentiation was similar. On the other hand, the gene
expression of other growth factors (particularly Igf-2 and
Vegf-a) increased steadily as ESC differentiation pro-
gressed and yielded increased protein content in CM 9
and CM 12. The effects of the differential expression
and secretion of proteins by the differentiating ESCs
was further investigated by examining varied cellresponses during proliferation and migration experi-
ments comparing EB-CM collected at different days.
Overall, fibroblast migration was significantly stimu-
lated by all CM groups up to 12 hours, with the most ef-
fect seen in the first 6 hours, followed by a plateau, and
then decreasing for the remainder of the time course,
when only CM 9 induced significantly more migration
than uCM. While enhancing migration, CM 9 did not
stimulate fibroblast proliferation compared with CM 6
and CM 12, conditions that elicited roughly equivalent
levels of proliferation (Figures 4A and 5B). Distinct fibro-
blast behavior in response to CM 9 demonstrates the
unique combination of morphogens secreted by EBs after
9 days of differentiation – a secretome that stimulates
fibroblast migration, but inhibits proliferation; whereas
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moted fibroblast mitogenicity. Such a change in the
promotion of different cellular processes may reflect the
different stages of embryogenesis mimicked by ESCs
undergoing differentiation within EBs. Undifferentiated
ESCs typically proliferate at a high rate, which helps estab-
lish a critical mass for EB formation. As EB differentiation
proceeds, typically between 7 and 10 days, a sizable por-
tion of the cell population in the presence of serum pro-
teins undergoes an epithelial-to-mesenchymal transition,
which is characterized by the shift of nonmigratory epithe-
lial cells to more migratory mesenchymal phenotypes, simi-
lar to post-gastrulation embryonic development [39,40].
After epithelial-to-mesenchymal transition occurs, cells
comprising EBs continue to differentiate into more spe-
cific phenotypes and proliferation rates generally increase
yet again.
The response of ECs to EB-CM was different from that
of fibroblasts, which is probably to be expected based on
the phenotypic differences between these two cell popula-
tions. While the overall patterns of EC migration in re-
sponse to the EB-CM treatments largely followed those
of fibroblasts, and were significant compared with uCM
during the initial 12 hours of treatment, the number of
migrating ECs increased in response to CM 12 between
hours 12 and 24 (Figure 5D). The proliferative capacity
of ECs was also increased in response to CM 12 com-
pared with CM 6 and CM 9 (Figure 4B). Overall, the
complex mixture of morphogens secreted by day 12 EBs
was more mitogenic and motogenic relative to factors
secreted by day 6 and day 9 EBs. This complex combin-
ation of factors is analogous to the secretome produced
by EBs as they mature, typically from days 10 to 14 of
culture, when progenitor cells differentiate towards more
lineage-restricted cell types [31].
The growth factors secreted by EBs that were examined
in this study have been previously implicated in attenu-
ation of tissue damage and wound healing, including
regeneration of vasculature and bone. The persistence
of BMP-4 protein in the EB-CM from days 6 through
12 suggests the importance of this molecule throughout
early stages of ESC differentiation, specifically within
the mesoderm lineage, where BMP-4 has been impli-
cated in enhancing the formation of vascular networks
produced by mammalian ESC-derived EBs [41,42]. VEGF-
A is a well-documented growth factor capable of promot-
ing angiogenesis in ischemic tissues, where it is necessary
to promote an environment conducive to the effective
delivery of cells and nutrients required for stimulation
of tissue repair [43-45]. Many studies have demon-
strated the function of IGF-2 in the growth and differ-
entiation of skeletal muscle and bone tissue [44,46-48].
Moreover, IGFs and BMP-4 can increase VEGF expression
to synergistically stimulate tissue repair, and BMP-4 inconcert with VEGF treatment enhances bone formation
and healing compared with single-factor treatment [49].
Similarly, IGF-2 and VEGF together enhance angiogenesis
by promoting the homing of endothelial progenitor cells
[50], and the combination of IGF-1 and VEGF can target
multiple regenerative processes: angiogenesis, reinnerva-
tion, and myogenesis [51-53]. The increased production of
these growth factors by EBs at days 9 and 12 suggests that
early differentiating ESCs secrete factors that can posi-
tively affect tissue remodeling by stimulating regeneration
through induction of angiogenesis, coincident with other
morphogenic events.
Conclusions
Overall, this study demonstrates that factors secreted by
ESCs undergoing morphogenic differentiation as EBs are
capable of inducing proliferation and migration of ex-
ogenous somatic cell types, such as fibroblasts and ECs.
The complex mixture of ESC-secreted molecules contains
a number of different growth factors and morphogens
whose relative abundance varies as a function of EB dif-
ferentiation. Not surprisingly, the morphogenic events
known to be associated with EB differentiation, includ-
ing cell proliferation and migration, are reflected by the
endogenous expression of factors that comprise the se-
creted soluble milieu. Critically analyzing the composition
and bioactivity of molecules secreted by differentiating
ESCs thus not only provides insights into the paracrine
environment within the EB, but also suggests potential
trophic mechanisms whereby differentiated progeny from
ESCs can beneficially impact exogenous cells commonly
involved in tissue remodeling and regeneration processes.
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